Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

• Status: Recruiting
• Trial end date: 2026-06-01
• Target enrollment: 0
• Participant gender: All

Summary

12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ACADIA Pharmaceuticals Inc.
• Treatments: Carbetocin

Criteria

Inclusion Criteria:

• Male or female and 5 through 30 years of age

• Prader-Willi syndrome with a documented disease-causing mutation

• Increased appetite with decreased satiety accompanied by food seeking (consistent with PWS Nutritional Phase 3)

• HQ-CT total score of ≥13 at Screening and Baseline

• CGI-S score for hyperphagia in PWS of ≥4 at Screening and Baseline

• Lives with a caregiver who understands and is willing and able to adhere to study-related procedures and is willing to participate in all study visits

Exclusion Criteria:

• Genetically diagnosed with Schaaf-Yang syndrome or another genetic, hormonal, or chromosomal cognitive impairment besides PWS

• An active upper respiratory infection at the Screening visit or the Baseline visit

• Any clinically significant cardiovascular disorder, renal, hepatic, gastrointestinal, or respiratory disease, including severe asthma

• History of, or current, cerebrovascular disease, brain trauma, epilepsy, or frequent migraines. A history of febrile seizures is not exclusionary

• Nasal surgery within 1 month of Screening visit or planning to have nasal surgery during the study.

• Unwilling to abstain from nasal saline, other nasal irrigation, and other intranasal medications during the Screening period and through the treatment period of the study

• Clinically significant irritability or agitation, requiring initiation of or increase in the dose of antipsychotic medication, within the 6 months prior to the Screening visit

• Used prostaglandins, prostaglandin analogues, or prostaglandin agonists in the 3 months prior to the Baseline visit. Inhibitors of prostaglandin synthesis, such as nonsteroidal anti-inflammatory drugs, are not exclusionary.

• Started a glucagon-like peptide 1 (GLP-1) agonist within the 6 months prior to the Screening visit. Treatment with GLP-1 agonist is allowed if the subject has been taking it for more than 6 months prior to Screening.

• Used oxytocin, desmopressin (DDAVP), or tesofensine within 6 months prior to the Baseline visit

• Active psychotic symptoms, a history of psychotic symptoms, or a psychotic disorder

• History of suicide attempt or inpatient psychiatric hospitalization

• New food-related interventions, including environment or dietary restrictions, within 1 month of the Screening visit

Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.